FDA Approves Personalized Cellular Therapy for Advanced Leukemia
August 30, 2017
In a landmark decision for the field of cancer immunotherapy, the U.S. Food and Drug Administration (FDA) today approved a personalized cellular therapy developed by the University of Pennsylvania and Children’s Hospital of Philadelphia (CHOP) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
Read the Department of Communications news release.
New York Times
Wall Street Journal
National Institutes of Health